Acquisition expands Glooko's digital health capabilities with machine learning

BERLIN and PALO ALTO, Calif ., Feb. 1, 2022 /PRNewswire/ -- Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic diseases, announced today the acquisition of xbird, a Berlin-based company specializing in medical artificial intelligence that develops JITAI (just-in-time adaptive interventions) technologies to help patients and their providers predict behavior and manage diabetes.

Using the latest artificial intelligence and machine learning, xbird's technology is able to identify health risks for people with diabetes by interpreting medical and behavioral data in a targeted way and providing recommendations. personalized and behavioral encouragement. Sensors via smartphones and wearable devices record a user's movements and analyze the data to create individualized behavioral profiles and personalized encouragement to change patient behavior and lifestyle decisions. The addition of xbird expands Glooko's advanced analytics capabilities and tools, expanding the offerings of the Glooko platform.

“We are delighted to welcome the xbird team to the Glooko family. Our investment in xbird represents Glooko's strategic commitment to machine learning and personalized digital coaching for patients with chronic conditions,” said Russ Johannesson , CEO of Glooko. “Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution and has established successful partnerships with diabetes monitoring device manufacturers and clinical institutions. The combination of Glooko's established global footprint and xbird's exciting JITAI capabilities will enable us to improve patient outcomes. »

Sebastian Sujka , CEO and co-founder of xbird, said, “xbird and Glooko are an ideal choice. We share a commitment to providing solutions that address multiple chronic conditions and produce measurable results, and we have a common mission to globally serve all patients with needs. Our goal is to continue to design digital health solutions for people living with these diseases and to make our capabilities accessible to as many patients as possible. Sebastian Sujka will join Glooko as Managing Director of Glooko GmbH, along with all xbird staff.

Glooko will integrate the xbird JITAI digital coaching software into its established platform which is used daily by more than 7,500 clinics worldwide and over 1 million users. Glooko plans to enable global users of its platform to use these solutions to better manage their diabetes and related chronic conditions.

Prevalence of chronic diseases*
Approximately 537 million adults have diabetes worldwide, including 9.5 million in Germany (15.3% of the population) and the numbers continue to rise. It is ranked in the top 10 countries with the fastest growing diabetes. In addition, almost one in two people over the age of 15 in Germany report living with two or more chronic diseases (compared to around one third of people worldwide). According to the European Observatory on Health Systems and Policies, one in six adults in Germany is considered obese.

About Glooko
Glooko is transforming digital health by connecting people living with diabetes and other chronic conditions with their healthcare teams, driving collaborative telehealth, clinical research and improving health outcomes. The company's software platforms collect and analyze data from multiple devices in one highly secure location, allowing for easy remote download via app or in-clinic, and producing easy-to-read analytics through charts and graphs. actionable graphics. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in managing their conditions. More than 3 million users have already benefited from Glooko's solutions in 29 countries and 22 languages. For more information, visit glooko.com.

About xbird
xbird is a medical artificial intelligence company developing ways to predict health risks and support diabetes management. The company captures data streams from embedded sensors on smartphones, wearables and medical devices to develop algorithms and machine learning models that process these streams into just-in-time (JITAI) adaptive interventions in time real. Founded in 2015 by Sebastian Sujka and Matteo Carli , xbird has collaborated with major European and American pharmaceutical and medical device companies to personalize patient interaction and engagement with artificial intelligence.